Biodesix, Inc.

AI-generated fair value estimate for this company.

Method: 10-year revenue-and-margin-ramp DCF: revenue base $102.94M TTM growing 10% in year 1 (in line with $108-114M FY2026 guidance), decelerating to 5% by year 10; FCF margin improving from approximately -20% currently to +18% by year 10 as the company scales toward profitability; 11% discount rate; 3% terminal growth; -$41.80M net debt; 10.55M shares outstanding.

Reasoning: Biodesix is a high-growth, currently loss-making diagnostics company (revenue up 34-42% year over year recently), so a static current-FCF DCF is inappropriate; a growth-to-maturity model projecting the path from cash burn to a mature diagnostics-company FCF margin better captures its value. The higher discount rate reflects execution and reimbursement risk.